- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Dexamethasone, Elotuzumab, Linvoseltamab, Pomalidomide
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 1,149
matching trials from the local directory fallback.
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Teclistamab
- Drug
- Lead sponsor
- European Myeloma Network B.V.
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more
- Conditions
- Aortic Valve Insufficiency, Aortic Valve Stenosis
- Interventions
- SAPIEN X4/X4S THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2039
- U.S. locations
- 34
- States / cities
- Newport Beach, California • San Francisco, California • Stanford, California + 26 more
- Conditions
- Leiomyosarcoma, Liposarcoma, Retroperitoneal Sarcoma
- Interventions
- Preoperative chemotherapy, Surgery
- Drug · Procedure
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more
- Conditions
- Colorectal Cancer, Sarcopenia
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 147
- States / cities
- Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 114 more
- Conditions
- Cutaneous Lupus Erythematosus, Systematic Lupus Erythematosus
- Interventions
- Enpatoran, Placebo, Standard of care (SoC)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
- Conditions
- Knee Cartilage Defects
- Interventions
- CARTISTEM® + Debridement, Debridement
- Biological · Procedure
- Lead sponsor
- Medipost, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 26 more
- Conditions
- Ovarian Cancer, PSOC, Platinum-sensitive Ovarian Cancer
- Interventions
- Bevacizumab, Rina-S
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Miami, Florida • Sarasota, Florida • Towson, Maryland + 6 more
- Conditions
- Breast Neoplasms
- Interventions
- Carboplatin, Eribulin, Gemcitabine, Matching placebo, Nab-paclitaxel/Paclitaxel, Pumitamig
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 71
- States / cities
- Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more
- Conditions
- Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
- Interventions
- IC, Rina-S
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Irvine, California + 51 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, GDC-4198, Giredestrant
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Duarte, California + 28 more
- Conditions
- Agitation, Alzheimer Disease
- Interventions
- BMS-986368, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Breast Cancer
- Interventions
- CDK4/6i, Inavolisib, Letrozole, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 62
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Palbociclib 125mg, Ribociclib, Ribociclib 600mg
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more
- Conditions
- Multiple Myeloma
- Interventions
- Arlocabtagene Autoleucel
- Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Bendamustine, Cyclophosphamide, Doxorubicin, Odronextamab, Prednisone/prednisolone, Rituximab, Vincristine
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
- Conditions
- cGVHD
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
- Conditions
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Interventions
- Abemaciclib, Atezolizumab, Everolimus, Giredestrant, Inavolisib, Ipatasertib, PH FDC SC, Palbociclib, Ribociclib, Samuraciclib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 12
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 9 more
- Conditions
- Carcinoma, Squamous Cell, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, EGFR Amplification, Epithelial Ovarian Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Pancreas Cancer, Squamous Cell Carcinoma of Anal Canal, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of the Lung
- Interventions
- BCA101, Pembrolizumab
- Drug
- Lead sponsor
- Bicara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Darolutamide, Docetaxel, Enzalutamide, Rinzimetostat
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Atlanta, Georgia + 9 more
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- IDRX-42, Sunitinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 42 more
- Conditions
- Heart Failure - NYHA II - IV
- Interventions
- CRT-D with INGEVITY+ pace/sense lead, CRT-D with a Quadripolar LV lead
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
- Conditions
- Device Related Thrombosis, Peri-device Leak
- Interventions
- Cardiac CTA, Transesophageal echocardiography (TEE)
- Procedure
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more